Breaking News

BioNTech and Ryvu Therapeutics Enter Multi-Target Research Collaboration

Will develop and commercialize immuno-modulatory small molecule candidates.

Author Image

By: Charlie Sternberg

Associate Editor

BioNTech SE and Ryvu Therapeutics S.A., a clinical-stage company developing oncology therapeutics, have entered into a multi-target research collaboration for several small molecule immunotherapy programs as well as an exclusive license agreement for Ryvu’s STING agonist portfolio as standalone small molecules.   The global collaboration will consist of two parts:   BioNTech will receive a global, exclusive license to develop and commercialize Ryvu’s STING agonist portfolio as standal...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters